Latest Patent Protection News

Page 1 of 11
Neuren has lifted its 2026 trofinetide income guidance to US$91 million-US$93 million after Acadia reported a 39% rise in Q3 DAYBUE sales and a US$35 million German launch milestone. Japan trial results also support a planned 2027 regulatory filing, although a launch remains subject to approval and a distribution partner.
Victor Sage
Victor Sage
5 Nov 2026
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
Mayne Pharma has settled its final US Paragraph IV patent dispute over IMVEXXY with Teva, setting a potential generic entry date of 2 September 2032. The agreement removes ongoing litigation without an upfront payment, while leaving court approval and earlier-entry provisions to resolve.
Victor Sage
Victor Sage
16 Oct 2026
Firebird Metals is moving from manganese exploration towards downstream battery materials, with its Perth demonstration plant backed by a A$2 million ARENA grant. But the ASX-listed company remains loss-making, has A$3.61 million in cash and faces a material uncertainty over its ability to continue without further funding.
Victor Sage
Victor Sage
29 Sept 2026
Neuren says its partner Acadia has received a US Notice of Allowance for a trofinetide patent that could protect weight-banded dosing through 28 March 2041. The patent has not yet formally issued, but the allowance could extend US protection by almost five years beyond the existing method-of-use patent.
Ada Torres
Ada Torres
29 Sept 2026
Dimerix has secured Mexican composition of matter protection for its Phase 2-ready kidney drug DMX-652 until June 2041. The grant expands the asset’s patent estate ahead of planned clinical testing in acute kidney injury, although it brings no new clinical data or regulatory approval.
Victor Sage
Victor Sage
14 Sept 2026
Phoslock Environmental Technologies has advanced a new range of lanthanum-enhanced phosphorus-binding products showing up to four times the capacity of current offerings, with pilot and manufacturing tests confirming strong performance and low lanthanum release. Field trials are underway, aiming for commercial sales in 2027.
Maxwell Dee
Maxwell Dee
7 Sept 2026
AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.
Ada Torres
Ada Torres
21 Aug 2026
Mount Ridley Mines has lodged a provisional patent for its SelectroTM hydrometallurgical leach technology, demonstrating superior recoveries of rare earths, scandium, and gallium compared to conventional methods. The company is advancing testwork and commercial discussions to capitalise on the innovation.
Maxwell Dee
Maxwell Dee
19 Aug 2026
Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.
Ada Torres
Ada Torres
13 Aug 2026
InFocus Group Holdings has rolled out a major upgrade to its Codexa sweepstakes casino platform, introducing a VIP-style player experience and a proprietary AI-driven compliance engine designed to streamline operations and reduce costs for white-label operators.
Sophie Babbage
Sophie Babbage
12 Aug 2026
Talga Group has marked a milestone with its first commercial delivery of natural graphite anode outside Asia, progressing key funding discussions and strategic partnerships to support its Vittangi Anode Project.
Maxwell Dee
Maxwell Dee
30 July 2026

Browse the archive

Full archive